Type 1 diabetes is one of the most common endocrine and metabolic conditions in childhood. Poor metabolic control may result in the acute complications of hypoglycaemia and ketoacidosis, chronic microvascular and macrovascular complications and death. Since T1D patients have few functional pancreatic β-cells, an external supply of insulin or the addition of functional pancreatic β-cell is required for glycemic control.

About 29 million people in US are affected by diabetes. In terms of revenue the North American region accounts for over 1/3 of the insulin delivery devices market share. Also the prevalence of diabetes is growing in Canada. As an increased number of patient base which is suffering from diabetes and its increasing prevalence across many other nations is boosting the market of insulin delivery devices.

We are working with our partners to develop the immuno-isolation technology for successfully engrafting the allo-/xeno-transplantation of insulin-secreting islets, even without the usage of immunosuppressant.